title: Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010).
authors.affiliation: BioLineRx Ltd, Jerusalem, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Levy-Nissenbaum
authors.affiliation: Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.
authors.forename: H B
authors.initials: HB
authors.lastname: Thio
authors.affiliation: Innovative Pharmaceutical Concepts Inc., Ramat HaSharon, Israel.
authors.forename: P
authors.initials: P
authors.lastname: Burstein
authors.affiliation: Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Lübeck, Lübeck, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Thaci
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002424:Caustics / Q000008:administration & dosage*; D004338:Drug Combinations; D005561:Formates / Q000008:administration & dosage*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D017492:Keratosis, Seborrheic / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome; D014238:Trichloroacetic Acid / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: C000606537:BL-5010; D002424:Caustics; D004338:Drug Combinations; D005561:Formates; D007641:Keratolytic Agents; C030544:formic acid; D014238:Trichloroacetic Acid